# Targeting Oxidative Stress in Chronic Beryllium Disease

> **NCT01088243** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Jewish Health** · enrollment: 18 (actual)

## Conditions studied

- Chronic Beryllium Disease

## Interventions

- **DRUG:** Mesalamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01088243
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088243, "Targeting Oxidative Stress in Chronic Beryllium Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01088243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*